Alvocidib prodrugs having increased bioavailability
US9758539B2 · kind B2 · utility
22Cited by
7References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 18, 2016 |
| Grant date | Sep 12, 2017 |
| Priority date | — |
| Expiry date | May 18, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D405/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds having the following structure (I):or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein one of R1, R2 or R3 is —P(═O)(OH)2, and the other two of R1, R2 and R3 are each H, are provided. Pharmaceutical compositions comprising the compounds, and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.